



## Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 29, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- [Enanta Pharmaceuticals, Inc.](https://www.enanta.com) (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.

A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at [www.enanta.com](https://www.enanta.com). A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

### About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit <http://www.enanta.com> for more information.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240529474424/en/>

### Media and Investors:

Jennifer Viera  
[jviera@enanta.com](mailto:jviera@enanta.com)

Source: Enanta Pharmaceuticals, Inc.